IP Library Granted Patent US 9,085,533
Granted Patent B2
US 9,085,533 · App. 14/382,967 · Granted Jul 21, 2015

Process for preparation of roflumilast

Inventors: Yi-Jing Chen (Meishan Township, TW); Stanislaw Pikul (Windsor, NJ); Shen-Chun Kuo (Union, NJ); Guo-dong Chu (Jiaxiang County, CN)
Assignee: ScinoPharm (Changshu) Pharmaceuticals, Ltd.
C07D213/75C07C43/2055C07C43/315C07D213/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,085,533
App. No.
14/382,967
Granted
Jul 21, 2015
Kind
B2
Abstract

The present invention provides novel processes for the preparation of N-substituted benzamides having the formula (VIc). In some embodiments, the invention provides a process for preparation of roflumilast and other pharmaceutically active species. Novel compounds, including intermediates for the synthesis of roflumilast, are also provided.

Claims (31)

1. A process for the preparation of a compound of formula VIc

the process comprising:

a) reacting a compound of formula IIc

with an aldehyde protecting reagent to provide a compound of formula IIIc

b) reacting the compound of formula IIIc with a compound of formula IVa

to provide a compound of formula Vc

in a one-pot reaction; and

c) oxidizing the compound of formula Vc to provide the compound of formula VIc;

wherein

R 1 and R 2 are independently selected from the group consisting of H; C 1-6 alkyl; C 3-7 cycloalkyl; C 3-7 cycloalkylmethyl; and C 1-4 alkyl which is partially or completely substituted with fluorine;

R 4 and R 5 are independently selected from the group consisting of C 1-6 alkyl and acyl; or

R 4 and R 5 are taken together to form an optionally substituted 5-7 member cyclic ring.

2. The process of claim 1 , wherein:

step a) is conducted in a non-polar organic solvent in the presence of an acid.

3. The process of claim 2 , wherein the non-polar organic solvent is selected from the group consisting of toluene and xylene.

4. The process of claim 2 , wherein the acid is selected from the group consisting of p-toluenesulfonic acid, camphorsulfonic acid, polymeric resin based sulfonic acid and acetic acid.

5. The process of claim 1 , wherein the aldehyde protecting reagent is selected from the group consisting of trimethyl orthoformate, triethyl orthoformate, triethyl orthoacetate, trimethyl orthoacetate, acetic anhydride and ethylene glycol.

6. The process of claim 1 , wherein step c) comprises an oxidant selected from the group consisting of a chlorite, a transition metal catalyst, nickel peroxide, m-CPBA, TBHP, potassium peroxomonosulfate and mixtures thereof.

7. The process of claim 6 , wherein the chlorite is selected from the group consisting of chlorous acid, magnesium chlorite, sodium chlorite and potassium chlorite.

8. The process of claim 6 , wherein the chlorite is buffered with an electrolyte selected from the group consisting of HCl/sodium citrate, citric acid/sodium citrate, acetic acid/sodium citrate, potassium dihydrogen phosphate, dipotassium phosphate/sodium dihydrogen phosphate, acetic acid and disodium phosphate.

9. The process of claim 1 , wherein the compound of formula VIc is:

10. A process for the preparation of a compound of formula VIc

the process comprising:

a) reacting a compound of formula IIc

with a compound of formula IVa

in the presence of a Lewis acid catalyst and/or a silylation reagent to form the compound of formula Vc;

and

b) oxidizing the compound of formula Vc to provide the compound of formula VIc;

wherein R 1 and R 2 are independently selected from the group consisting of H; C 1-6 alkyl; C 3-7 cycloalkyl; C 3-7 cycloalkylmethyl; and C 1-4 alkyl which is partially or completely substituted with fluorine.

11. The process of claim 10 , wherein the Lewis acid is selected from the group consisting of TMSOTf, TMSCl, PTSA, TfOH, MSA, TFA and mixtures thereof.

12. The process of claim 10 , wherein the silylation reagent is selected from the group consisting of BSA, BSTFA and mixtures thereof.

Assignments (2)
CHANGE OF NAME Recorded Sep 10, 2020
From: SCINOPHARM (CHANGSHU) PHARMACEUTICAL, LTD.
To: SCIANDA (CHANGSHU) PHARMACEUTICALS, LTD.
Reel/Frame 053746/0176 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2014
From: CHEN, YI-JING; PIKUL, STANISLAW; KUO, SHEN-CHUN; CHU, GUO-DONG
To: SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD.
Reel/Frame 034532/0371 →
Priority Claims (1)
WO PCT/CN2012/072020 · Mar 7, 2012 · international
Continuity (1)
Related Publication 20150025246A1 · Jan 22, 2015